Johnson & Johnson Appoints Former Roche Executive Chen Yanli as HR Head for MedTech China and OneHR China

Apr 22, 2024 17:31 CST Updated 17:31

Johnson & Johnson

Medical Device R&D and Manufacturer

According to "Luo Shi Xiong" news, Johnson & Johnson announced that Chen Yanli will assume the role of Human Resources Leader for Johnson & Johnson Medical Technology China & OneHR China on April 29. She will join the Board of Directors of Johnson & Johnson Medical Technology China and the Asia-Pacific Human Resources Management Team.

Chen Yanli will be responsible for providing human resources-related support to the business from both operational and strategic perspectives, driving business growth by building talent strategies. Meanwhile, as the head of OneHR in China, she will also work closely with the China President’s Council and the Human Resources Committee to advance the human resources strategy for One J&J in China.

Data shows that Chen Yanli once served as the Director of Human Resources for Dow Chemical's Asia-Pacific region and was a member of both the Asia-Pacific management team and the global human resources management team. During her 13-year career at Dow, Chen Yanli successively held positions such as Director of Human Resources for Greater China, HR Business Partner for the Asia-Pacific Commercial and Business Development Department, and Head of International Assignments for the Asia-Pacific region.

In 2019, Chen Yanli joined Roche as the Vice President of Talent and Organizational Culture at Roche Pharmaceuticals China. In 2022, her role expanded to also lead the Hospital Key Account Management Department for Market Access in China. On April 11 this year, Roche announced Chen Yanli's departure.

Q1 Earnings Report Released

On April 16, Johnson & Johnson released its Q1 2024 financial report: Global sales reached $21.4 billion, a year-on-year increase of 2.3%; including $13.6 billion in innovative pharmaceutical sales and $7.8 billion in medical technology sales.

The growth in the innovative pharmaceuticals sector was primarily driven by autoimmune products such as Stelara (ustekinumab) and Tremfya (guselkumab), as well as oncology products like Carvykti (cilta-cel) and Darzalex (daratumumab). Notably, Carvykti's sales surged 118% year-over-year, reaching $157 million.

In the medical technology field, the cardiovascular business performed remarkably, with Q1 revenue reaching $1.806 billion, a year-on-year increase of 20.2%; among which, the electrophysiology business revenue reached $1.344 billion, growing by 23% year-on-year.

Johnson & Johnson forecasts full-year 2024 sales of $88.7 billion to $89.1 billion, up from the previous estimate of $88.2 billion to $89.0 billion.

$13.1 Billion Mega-Acquisition

Recently, Johnson & Johnson also announced a major acquisition: Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, with a total transaction value of approximately $13.1 billion, including the acquisition cash. Through this transaction, Johnson & Johnson will gain access to the only commercially available intravascular lithotripsy (IVL) technology and a new product designed to alleviate symptoms of refractory angina.

At the same time, Johnson & Johnson Medical Technologies is expanding its investment and increasing production capacity. In February this year, Johnson & Johnson Medical Technologies announced an investment of $168 million to expand its factory in Manatí, Puerto Rico, to enhance the production capacity of key Ethicon products.

In terms of personnel, Johnson & Johnson Medical Technology announced on March 27 the appointment of Tulio Oliveira as the General Manager of the China Surgical Division.

References:

[1] Johnson & Johnson China: "Accelerating to Lead! Johnson & Johnson Announces First Quarter Results"

[2] Luo Shixiong: "Johnson & Johnson Appoints New Leader"

[3] Luo Wet Brother: "Breaking, Roche's Leader Resigns"

[4] Pharmaceutical Economy News: "Major Mergers and Acquisitions: Johnson & Johnson Acquires Shockwave for $13.1 Billion, GE Healthcare Completes Acquisition of MIM Software, Labcorp Acquires Device Business for $237.5 Million"

[5] CPhI China: "Johnson & Johnson's Latest Earnings Report Released, This Business Grew Over 20%"

[6] PharmaCube: "Johnson & Johnson 2024 Q1: Darzalex Nearly $2.7 Billion, Carvykti Doubles Growth"

[7] Device Workplace: "New General Manager Appointed! Johnson & Johnson and Edwards Announce Successively"

Source: Siqi Club

Compiled by: Nicole

ClickRead the Original Text Learn More